Raras
Buscar doenças, sintomas, genes...
Neurodegenerescência associada a proteína de membrana mitocondrial
ORPHA:289560CID-10 · G23.0CID-11 · 5C64.10OMIM 614298DOENÇA RARA

A MPAN (Neurodegeneração Associada à Proteína da Membrana Mitocondrial), também conhecida como Neurodegeneração com Acúmulo de Ferro no Cérebro (NBIA) devido a mutações no gene C19orf12, é uma doença neurológica degenerativa autossômica recessiva. Isso significa que a pessoa precisa herdar uma cópia do gene alterado de cada um dos pais para desenvolver a condição. A MPAN é caracterizada pelo acúmulo de ferro em regiões específicas do cérebro, geralmente nos gânglios da base (áreas importantes para o controle do movimento). Ela está associada a sintomas que pioram lentamente, como rigidez muscular (espasticidade) e movimentos involuntários ou posturas anormais (distonia). Também causa problemas nos nervos que controlam os músculos (neuropatia motora axonal), perda progressiva da visão (atrofia do nervo óptico), perda de memória e dificuldade de raciocínio (declínio cognitivo), além de alterações psiquiátricas e de comportamento.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A MPAN (Neurodegeneração Associada à Proteína da Membrana Mitocondrial), também conhecida como Neurodegeneração com Acúmulo de Ferro no Cérebro (NBIA) devido a mutações no gene C19orf12, é uma doença neurológica degenerativa autossômica recessiva. Isso significa que a pessoa precisa herdar uma cópia do gene alterado de cada um dos pais para desenvolver a condição. A MPAN é caracterizada pelo acúmulo de ferro em regiões específicas do cérebro, geralmente nos gânglios da base (áreas importantes para o controle do movimento). Ela está associada a sintomas que pioram lentamente, como rigidez muscular (espasticidade) e movimentos involuntários ou posturas anormais (distonia). Também causa problemas nos nervos que controlam os músculos (neuropatia motora axonal), perda progressiva da visão (atrofia do nervo óptico), perda de memória e dificuldade de raciocínio (declínio cognitivo), além de alterações psiquiátricas e de comportamento.

Pesquisas ativas
1 ensaio
1 total registrados no ClinicalTrials.gov
Publicações científicas
86 artigos
Último publicado: 2026 Apr

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.1
Worldwide
Início
Adolescent
+ adult, childhood
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G23.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
15 sintomas
💪
Músculos
5 sintomas
👁️
Olhos
4 sintomas
🫃
Digestivo
2 sintomas
🫁
Pulmão
1 sintomas
🫘
Rins
1 sintomas

+ 30 sintomas em outras categorias

Características mais comuns

90%prev.
Fraqueza muscular
Muito frequente (99-80%)
90%prev.
Tremor na mão
Muito frequente (99-80%)
90%prev.
Deterioração mental
Muito frequente (99-80%)
90%prev.
Instabilidade postural
Muito frequente (99-80%)
90%prev.
Espasticidade
Muito frequente (99-80%)
90%prev.
Rigidez
Muito frequente (99-80%)
58sintomas
Muito frequente (8)
Frequente (20)
Ocasional (6)
Muito raro (2)
Sem dados (22)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 58 características clínicas mais associadas, ordenadas por frequência.

Fraqueza muscularMuscle weakness
Muito frequente (99-80%)90%
Tremor na mãoHand tremor
Muito frequente (99-80%)90%
Deterioração mentalMental deterioration
Muito frequente (99-80%)90%
Instabilidade posturalPostural instability
Muito frequente (99-80%)90%
EspasticidadeSpasticity
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico86PubMed
Últimos 10 anos76publicações
Pico202113 papers
Linha do tempo
2026Hoje · 2026🧪 2012Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

C19ORF12Protein C19orf12Disease-causing germline mutation(s) inModerado
LOCALIZAÇÃO

MitochondrionMitochondrion membraneEndoplasmic reticulumCytoplasm, cytosol

MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 4

A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. NBIA4 results in speech difficulty, extrapyramidal signs, oromandibular and generalized dystonia, and parkinsonism. Most patients have progressive involvement of the corticospinal tract, with spasticity, hyperreflexia, and extensor plantar responses.

HGNC:25443UniProt:Q9NSK7
C19orf12Protein C19orf12Disease-causing germline mutation(s) inModerado
LOCALIZAÇÃO

MitochondrionMitochondrion membraneEndoplasmic reticulumCytoplasm, cytosol

MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 4

A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. NBIA4 results in speech difficulty, extrapyramidal signs, oromandibular and generalized dystonia, and parkinsonism. Most patients have progressive involvement of the corticospinal tract, with spasticity, hyperreflexia, and extensor plantar responses.

OUTRAS DOENÇAS (2)
neurodegeneration with brain iron accumulation 4hereditary spastic paraplegia 43
HGNC:HGNC:25443UniProt:Q9NSK7

Variantes genéticas (ClinVar)

144 variantes patogênicas registradas no ClinVar.

🧬 C19ORF12: NM_031448.6(C19orf12):c.224_234del (p.Gln75fs) ()
🧬 C19ORF12: NM_031448.6(C19orf12):c.271G>T (p.Glu91Ter) ()
🧬 C19ORF12: NM_031448.6(C19orf12):c.245del (p.Pro82fs) ()
🧬 C19ORF12: NM_031448.6(C19orf12):c.262C>T (p.Leu88Phe) ()
🧬 C19ORF12: NM_031448.6(C19orf12):c.246del (p.Ala83fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neurodegenerescência associada a proteína de membrana mitocondrial

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
80 papers (10 anos)
#1

Inflammation and oligoclonal bands in cerebrospinal fluid in neurodegeneration associated with C19orf12 mutations.

Parkinsonism &amp; related disorders2026 Feb

Analysis of cerebrospinal fluid examination can provide valuable information about the ongoing pathological processes in the central nervous system. To demonstrate chronic inflammation, oligoclonal bands (OCB) are detected and are typical of chronic demyelinating disease-multiple sclerosis (MS). This study aimed to detect OCB and white matter hyperintensities in patients with C19orf12 mutations. Thirteen patients with C19orf12 mutations causing mitochondrial membrane protein-associated neurodegeneration (MPAN) were examined. Eight patients exhibited oligoclonal bands, with 6 having type 3 and 2 having type 2. All patients with OCB and 3 without OCB showed myelin loss. Our findings, which reveal chronic inflammation in NBIA-MPAN alongside myelin loss, provide new insights into disease pathology and promote discussion of anti-inflammatory treatments in C19orf12 carriers.

#2

Autophagy-related proteomics reveals lysosomal alterations linked to C19orf12 mutations and candidate biomarkers in MPAN patients' fibroblasts.

Neurobiology of disease2026 Feb

Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) is the third most common genetically-defined subtype of Neurodegeneration with Brain Iron Accumulation (NBIA), a group of rare, clinically heterogeneous disorders. The MPAN pathomechanism, including the link between C19orf12 mutations, iron accumulation, and metabolic alterations, is still poorly understood. While earlier research pointed to impaired autophagy in MPAN, a comprehensive understanding remains elusive. Here, we investigated the autophagy-linked proteome in primary fibroblasts derived from 18 MPAN patients and identified distinct alterations in autophagy-related protein expression. Importantly, a subset of these proteomic changes showed significant associations with disease severity, highlighting their potential relevance as biomarkers of clinical progression. Functional analyses further revealed increased lysosomal acidification as the most consistently affected autophagy-related process in MPAN fibroblasts. Notably, both proteomic and functional alterations were associated with C19orf12 mutation zygosity, underscoring its modulatory role in disease-relevant cellular pathways.

#3

Distinct Neurodegenerative Pathways in Two NBIA Subtypes: Inflammatory Activation in C19orf12 but Not in PANK2 Mutation Carriers.

Cells2025 Nov 17

Biomarker analysis in neurodegeneration with brain iron accumulation (NBIA) can offer valuable insights into the disease's pathology and natural history. Twenty-five patients with C19orf12 mutations causing mitochondrial membrane protein-associated neurodegeneration (MPAN), 12 patients with PANK2 mutations causing pantothenate kinase-associated neurodegeneration (PKAN), and 30 age- and gender-matched controls were studied. Serum levels of MMP-9, S100B, ICAM-1, E- and P-selectins, total α-synuclein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), Tau, ubiquitin-C-terminal hydrolase-L1 (UCH-L1), and brain-derived neurotrophic factor (BDNF) were measured. Clinical status was evaluated with dedicated rating scales. Compared to the control group, MPAN patients had significantly higher serum levels of nearly all biomarkers, except BDNF. NfL, GFAP, and UCH-L1, were elevated by 5, 2, and 3.5 times, respectively. PKAN patients showed no significant differences in GFAP, UCH-L1, and S100B levels compared to controls. However, NfL and Tau levels were increased by 3 and 1.8 times, respectively. A correlation was observed between disease severity and levels of NfL, Tau, and UCH-L1 in MPAN, and GFAP, Tau, and UCH-L1 in PKAN. Patients with MPAN and PKAN showed increased levels of neurodegeneration biomarkers. Elevated inflammation and blood-brain barrier dysfunction biomarkers were specific to MPAN patients.

#4

An Update and Perspectives on Mitochondrial Membrane Protein-Associated Neurodegeneration and C19orf12 Research.

Brain sciences2025 Jul 22

Mitochondrial Membrane Protein-Associated Neurodegeneration is a rare monogenic form of neurodegeneration characterized by iron accumulation in the brain. It is due to variants in the orphan gene C19orf12. Since its definition in 2011, many scientific groups have investigated the clinical features and molecular underpinnings of the disorder. In this review, we summarize the main points of progress in this field, trying to highlight the issues that need further attention and efforts to speed up the diagnostic path, improve the existing treatment options, and define targeted therapies.

#5

Novel Variant in C19orf12 Gene Causing Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) - Case Report and a Brief Review of Indian Literature on MPAN.

Annals of Indian Academy of Neurology2025 May 01

The purpose of this overview is to: 1.. Briefly describe the clinical characteristics of neurodegeneration with brain iron accumulation (NBIA); 2.. Review the genetic causes of NBIA; 3.. Review the differential diagnosis of NBIA with a focus on genetic conditions; 4.. Provide an evaluation strategy to identify the genetic cause of NBIA in a proband (when possible); 5.. Review high-level management of NBIA; 6.. Inform genetic counseling of family members of an individual with NBIA.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC42 artigos no totalmostrando 74

2026

Inflammation and oligoclonal bands in cerebrospinal fluid in neurodegeneration associated with C19orf12 mutations.

Parkinsonism &amp; related disorders
2026

Autophagy-related proteomics reveals lysosomal alterations linked to C19orf12 mutations and candidate biomarkers in MPAN patients' fibroblasts.

Neurobiology of disease
2025

Neurodegeneration With Brain Iron Accumulation and Ferroptosis Disorders in Children and Adults: An Imaging Review.

Journal of neuroimaging : official journal of the American Society of Neuroimaging
2025

Distinct Neurodegenerative Pathways in Two NBIA Subtypes: Inflammatory Activation in C19orf12 but Not in PANK2 Mutation Carriers.

Cells
2025

Patient-Derived Neurons Exhibit α-Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial Membrane Protein-Associated Neurodegeneration.

Movement disorders : official journal of the Movement Disorder Society
2025

An Update and Perspectives on Mitochondrial Membrane Protein-Associated Neurodegeneration and C19orf12 Research.

Brain sciences
2025

Neurodegeneration with Brain Iron Accumulation.

Advances in experimental medicine and biology
2025

Novel Variant in C19orf12 Gene Causing Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) - Case Report and a Brief Review of Indian Literature on MPAN.

Annals of Indian Academy of Neurology
2025

C19orf12 gene variants causing mitochondrial membrane protein-associated neurodegeneration (MPAN).

European journal of human genetics : EJHG
2024

Generation of four human induced pluripotent stem cell lines derived from patients with MPAN, subtype of NBIA, carrying the c.204_214del11 mutation in the C19orf12 gene.

Stem cell research
2025

Metabolic alterations in fibroblasts of patients presenting with the MPAN subtype of neurodegeneration with brain iron accumulation (NBIA).

Biochimica et biophysica acta. Molecular basis of disease
2025

Metabolic impairments in neurodegeneration with brain iron accumulation.

Biochimica et biophysica acta. Bioenergetics
2024

Mitochondrial Membrane Protein-Associated Neurodegeneration with Brain Iron Accumulation: Diagnosis by MRI.

Neurology India
2024

Genetic Targets and Applications of Iron Chelators for Neurodegeneration with Brain Iron Accumulation.

ACS bio &amp; med chem Au
2024

Teaching NeuroImage: Mitochondrial Membrane Protein-Associated Neurodegeneration: An MRI Pattern Recognition.

Neurology
2024

Mitochondrial-Membrane-Protein-Associated Neurodegeneration in Longitudinal Magnetic Resonance Imaging Over 11 Years of Follow-Up.

Journal of clinical neurology (Seoul, Korea)
2024

Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders.

Movement disorders clinical practice
2023

'Comb Sign': A Novel Appearance of Substantia Nigra in Mitochondrial Membrane Protein-Associated Neurodegeneration.

Annals of Indian Academy of Neurology
2023

Rehabilitation for Mitochondrial Membrane Protein-Related Neurodegeneration: A Case Study.

Cureus
2024

Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration.

Brain : a journal of neurology
2023

Generation of two human iPSC lines, HMGUi004-A and FINCBi004-A, from fibroblasts of MPAN patients carrying pathogenic recessive mutations in the gene C19orf12.

Stem cell research
2024

Olfactory status in neurodegeneration with brain iron accumulation disorders.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2023

Autosomal Dominant MPAN: Mosaicism Expands the Clinical Spectrum to Atypical Late-Onset Phenotypes.

Movement disorders : official journal of the Movement Disorder Society
2023

A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone.

BMC neurology
2022

Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN): Two Phenotypes-Dystonia and Spastic Paraparesis.

Annals of Indian Academy of Neurology
2023

A novel C19orf12 frameshift mutation in a MPAN pedigree impairs mitochondrial function and connectivity leading to neurodegeneration.

Parkinsonism &amp; related disorders
2023

Identification of Autophagy as a Functional Target Suitable for the Pharmacological Treatment of Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) In Vitro.

Pharmaceutics
2022

Manic syndrome in mitochondrial membrane protein-associated neurodegeneration: A case report.

Psychiatry and clinical neurosciences
2022

Case Report: Identification of a De novo C19orf12 Variant in a Patient With Mitochondrial Membrane Protein-Associated Neurodegeneration.

Frontiers in genetics
2022

Two cases with mitochondrial membrane protein-associated neurodegeneration: genetic features and long-term clinical follow-up.

Neurocase
2021

Novel C19orf12 loss-of-function variant leading to neurodegeneration with brain iron accumulation.

Neurocase
2021

NBIA Syndromes: A Step Forward from the Previous Knowledge.

Neurology India
2021

Mitochondrial Membrane Protein-associated Neurodegeneration due to Novel Homozygous Mutation in the C19orf12 Gene.

Annals of Indian Academy of Neurology
2021

Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration.

Developmental medicine and child neurology
2021

Challenges in the approach and reporting of atypical manifestations of membrane protein-associated neurodegeneration (MPAN): An editorial.

Parkinsonism &amp; related disorders
2021

C19orf12 mutation causing mitochondrial membrane-protein Associated Neurodegeneration masquerading as spastic paraplegia.

Parkinsonism &amp; related disorders
2021

A De Novo case of autosomal dominant mitochondrial membrane protein-associated neurodegeneration.

Molecular genetics &amp; genomic medicine
2021

Distal muscle weakness and optic atrophy without central nervous system involvement in a patient with a homozygous missense mutation in the C19ORF12-gene.

Clinical neurology and neurosurgery
2021

Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

Frontiers in neurology
2020

Mitochondrial Membrane Protein-Associated Neurodegeneration: A Case Series of Six Children.

Annals of Indian Academy of Neurology
2021

Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases.

Frontiers in neuroscience
2021

Retrospective analysis of 17 patients with mitochondrial membrane protein-associated neurodegeneration diagnosed in Russia.

Parkinsonism &amp; related disorders
2021

Cardiac disease in mitochondrial membrane protein-associated neurodegeneration (MPAN) due to variants in C19orf12.

Parkinsonism &amp; related disorders
2020

The Downregulation of c19orf12 Negatively Affects Neuronal and Musculature Development in Zebrafish Embryos.

Frontiers in cell and developmental biology
2021

Dominant mitochondrial membrane protein-associated neurodegeneration (MPAN) variants cluster within a specific C19orf12 isoform.

Parkinsonism &amp; related disorders
2020

Novel dominant MPAN family with a complex genetic architecture as a basis for phenotypic variability.

Neurology. Genetics
2020

Reprogramming of a human induced pluripotent stem cell (iPSC) line from a patient with neurodegeneration with brain iron accumulation (NBIA) harboring a novel frameshift mutation in C19orf12 gene.

Stem cell research
2020

Is there heart disease in cases of neurodegeneration associated with mutations in C19orf12?

Parkinsonism &amp; related disorders
2020

Late-Onset Mitochondrial Membrane Protein-Associated Neurodegeneration With Extensive Brain Iron Deposition.

Movement disorders clinical practice
2019

Clinical and genetic spectrum of an orphan disease MPAN: a series with new variants and a novel phenotype.

Neurologia i neurochirurgia polska
2019

A Novel Mutation in Neurodegeneration with Brain Iron Accumulation - A Case Report.

Neurology India
2019

[Pedigree analysis of C19ORF12 p.Asp18Tyr mutation in a family with mitochondrial membrane protein associated neurodegeneration].

Zhonghua yi xue za zhi
2020

Brain iron and metabolic abnormalities in C19orf12 mutation carriers: A 7.0 tesla MRI study in mitochondrial membrane protein-associated neurodegeneration.

Movement disorders : official journal of the Movement Disorder Society
2019

Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN).

Molecular genetics &amp; genomic medicine
2019

Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration.

Neurology. Clinical practice
2019

Mitochondrial Membrane Protein Associated Neurodegeneration   (MPAN) with a Novel C19orf12 Mutation in the First Decade of Life.

Indian journal of pediatrics
2018

Mitochondrial membrane protein-associated neurodegeneration: a case report and literature review.

Neurocase
2017

Mitochondrial membrane protein-associated neurodegeneration.

Parkinsonism &amp; related disorders
2018

Transcranial Sonography in Mitochondrial Membrane Protein-Associated Neurodegeneration.

Clinical neuroradiology
2017

The p.Thr11Met mutation in c19orf12 is frequent among adult Turkish patients with MPAN.

Parkinsonism &amp; related disorders
2017

Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12.

Parkinsonism &amp; related disorders
2017

A Novel Deletion Mutation of Exon 2 of the C19orf12 Gene in an Omani Family with Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN).

Oman medical journal
2016

Mitochondrial membrane protein-associated neurodegeneration in a Turkish patient.

Journal of pediatric neurosciences
2016

Clinical and imaging characteristics of late onset mitochondrial membrane protein-associated neurodegeneration (MPAN).

Neurocase
2016

Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN).

Journal of the neurological sciences
2016

Mitochondrial Membrane Protein-Associated Neurodegeneration Mimicking Juvenile Amyotrophic Lateral Sclerosis.

Pediatric neurology
2016

A diagnostic approach for neurodegeneration with brain iron accumulation: clinical features, genetics and brain imaging.

Arquivos de neuro-psiquiatria
2016

Movement disorders in mitochondrial diseases.

Revue neurologique
2016

"Eye of tiger sign" mimic in an adolescent boy with mitochondrial membrane protein associated neurodegeneration (MPAN).

Brain &amp; development
2015

Behr syndrome with homozygous C19ORF12 mutation.

Journal of the neurological sciences
2015

C19orf12 gene mutations in patients with neurodegeneration with brain iron accumulation.

Parkinsonism &amp; related disorders
2015

Eye of the tiger sign in a 23 year patient with mitochondrial membrane protein associated neurodegeneration.

Journal of the neurological sciences
2015

Analysis of the C19orf12 and WDR45 genes in patients with neurodegeneration with brain iron accumulation.

Journal of the neurological sciences
2014

Brain iron quantification by MRI in mitochondrial membrane protein-associated neurodegeneration under iron-chelating therapy.

Annals of clinical and translational neurology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neurodegenerescência associada a proteína de membrana mitocondrial.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neurodegenerescência associada a proteína de membrana mitocondrial

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Inflammation and oligoclonal bands in cerebrospinal fluid in neurodegeneration associated with C19orf12 mutations.
    Parkinsonism &amp; related disorders· 2026· PMID 41483640mais citado
  2. Autophagy-related proteomics reveals lysosomal alterations linked to C19orf12 mutations and candidate biomarkers in MPAN patients' fibroblasts.
    Neurobiology of disease· 2026· PMID 41478510mais citado
  3. Distinct Neurodegenerative Pathways in Two NBIA Subtypes: Inflammatory Activation in C19orf12 but Not in PANK2 Mutation Carriers.
    Cells· 2025· PMID 41294854mais citado
  4. An Update and Perspectives on Mitochondrial Membrane Protein-Associated Neurodegeneration and C19orf12 Research.
    Brain sciences· 2025· PMID 40867110mais citado
  5. Novel Variant in C19orf12 Gene Causing Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) - Case Report and a Brief Review of Indian Literature on MPAN.
    Annals of Indian Academy of Neurology· 2025· PMID 40223318mais citado
  6. Neuropathologic Characterisation of Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) With Coexisting α-Synuclein and Tau Pathology in a Young Adult.
    Neuropathol Appl Neurobiol· 2026· PMID 41992069recente
  7. Phase separation of C19orf12 regulates BNIP3 protein quality control and maintains neuronal mitophagy.
    Autophagy· 2026· PMID 41937575recente
  8. Neurodegeneration With Brain Iron Accumulation and Ferroptosis Disorders in Children and Adults: An Imaging Review.
    J Neuroimaging· 2025· PMID 41320772recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:289560(Orphanet)
  2. OMIM OMIM:614298(OMIM)
  3. MONDO:0013674(MONDO)
  4. GARD:12569(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q32140736(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neurodegenerescência associada a proteína de membrana mitocondrial
Compêndio · Raras BR

Neurodegenerescência associada a proteína de membrana mitocondrial

ORPHA:289560 · MONDO:0013674
Prevalência
1-9 / 1 000 000
Herança
Autosomal recessive
CID-10
G23.0 · Doença de Hallervorden-Spatz
CID-11
Ensaios
1 ativos
Início
Adolescent, Adult, Childhood
Prevalência
0.1 (Worldwide)
MedGen
UMLS
C3280371
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades